



GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

24th May, 2019

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block

Bandra-Kurla Complex, Bandra (East)

Mumbai - 400051

Dear Sir,

Sub: Audited Financial Results Publication for Quarter & Year ended 31st March 2019

Pursuant to clause 47 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR) we enclose advertisements given in Economic Times, Business Standard and Maharashtra Times relating publication of Audited Financial Results for quarter and year ended 31st March 2019.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni

Vice President – Administration, Real Estate
& Company Secretary

Encl: Public Notice


GlaxoSmithKline Pharmaceuticals Limited

 Registered Office: Dr. Annie Besant Road, Mumbai 400030 • Website: www.gsk-india.com
 Email: askus@gsk.com • Corporate Identity Number: L24239MH1924PLC001151

**STATEMENT OF STANDALONE AND CONSOLIDATED AUDITED RESULTS
FOR THE YEAR ENDED 31st MARCH 2019**

(₹ in Lakhs)

	Standalone				Consolidated	
	Quarter Ended		Year Ended		Year Ended	
	Audited	Unaudited	Audited		Audited	
	3 months ended 31.03.19	Corresponding 3 months ended 31.03.18	31.03.19	31.03.18	31.03.19	31.03.18
Total Income from Operations	75122	74862	312853	289588	312812	289565
Profit before Exceptional Items	20233	16361	65882	52378	65397	52217
Profit before Tax	19916	16361	66371	54158	68266	53997
Net Profit	12303	10555	42536	35198	44539	35072
Total comprehensive income for the period	12296	10748	41987	35757	43990	35631
Paid-up Equity Share Capital (Face value per share ₹ 10)	16941	8470	16941	8470	16941	8470
Other Equity	0.00	0.00	197301	199525	197042	197263
Earnings Per Share (EPS) (of ₹ 10 each)						
Basic and diluted EPS (₹)	7.26	6.23	25.11	20.78	26.29	20.70
	Not Annualised					

Notes:

- The above is an extract of the detailed format of the Financial Results for the quarter and year ended 31st March 2019 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the website of the Company at www.gsk-india.com and on the website of Stock Exchanges at www.nseindia.com and www.bseindia.com.
- The Board of Directors recommends a Dividend of Rs. 20.00 per equity share of face value of Rs. 10 each (Year ended 31st March, 2018, Rs. 17.50 per equity share, retrospectively adjusted for September 2018 bonus issue).
- The above Results were approved by the Board of Directors at the Board meeting held on 20th May, 2019.


 20th May, 2019

 By Order of the Board
 Annaswamy Vaidheesh
 Managing Director
 DIN: 1444303

Mutual Funds

Aditya Birla Sun Life Mutual Fund



PROTECTING INVESTING FINANCING ADVISING

 Aditya Birla Sun Life AMC Limited (formerly known as Birla Sun Life Asset Management Company Ltd.) (Investment Manager for Aditya Birla Sun Life Mutual Fund) Registered Office: One India Bulls Centre, Tower 1, 17th Floor, Jupiter Mill Compound, 841, S.B. Marg, Elphinstone Road, Mumbai - 400 013. Tel: 4356 8000. Fax: 4356 8110/8111. CIN: U65991MH1994PLC080811

Record Date for Dividend

NOTICE IS HEREBY GIVEN THAT the Trustees of Aditya Birla Sun Life Mutual Fund ("the Fund") have approved the declaration of dividend in the following scheme of the Fund subject to availability of distributable surplus on the Record Dates*:

Name of the Scheme	Plans/Option	Quantum of Dividend # on face value of ₹ 10/-	Record Date*	NAV as on May 20,
--------------------	--------------	---	--------------	-------------------



GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai 400030 • Website: www.gsk-india.com
Email: askus@gsk.com • Corporate Identity Number: L24239MH1924PLC001151

STATEMENT OF STANDALONE AND CONSOLIDATED AUDITED RESULTS FOR THE YEAR ENDED 31st MARCH 2019

(₹ in Lakhs)

	Standalone				Consolidated	
	Quarter Ended		Year Ended		Year Ended	
	Audited	Unaudited	Audited		Audited	
	3 months ended 31.03.19	Corresponding 3 months ended 31.03.18	31.03.19	31.03.18	31.03.19	31.03.18
Total Income from Operations	75122	74862	312853	289588	312812	289565
Profit before Exceptional Items	20233	16361	65882	52378	65397	52217
Profit before Tax	19916	16361	66371	54158	68266	53997
Net Profit	12303	10555	42536	35198	44539	35072
Total comprehensive income for the period	12296	10748	41987	35757	43990	35631
Paid-up Equity Share Capital (Face value per share ₹ 10)	16941	8470	16941	8470	16941	8470
Other Equity	0.00	0.00	197301	199525	197042	197263
Earnings Per Share (EPS) (of ₹ 10 each)						
Basic and diluted EPS (₹)	7.26	6.23	25.11	20.78	26.29	20.70
	Not Annualised					

Notes:

- The above is an extract of the detailed format of the Financial Results for the quarter and year ended 31st March 2019 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the website of the Company at www.gsk-india.com and on the website of Stock Exchanges at www.nseindia.com and www.bseindia.com.
- The Board of Directors recommends a Dividend of Rs. 20.00 per equity share of face value of Rs. 10 each. (Year ended 31st March, 2018, Rs. 17.50 per equity share, retrospectively adjusted for September 2018 bonus issue).
- The above Results were approved by the Board of Directors at the Board meeting held on 20th May, 2019.

By Order of the Board

Annaswamy Vaidheesh

Managing Director

DIN: 1444303



20th May, 2019



व्हॅक्सोरिन्थक्लाइन फार्मास्युटिकल्स लिमिटेड

नोंदणीकृत कार्यालय : डॉ. अनी बेझंट रोड, मुंबई ४०००३० • वेबसाईट : www.gsk-india.com
ईमेल : askus@gsk.com • कॉर्पोरेट आयडेंटिटी क्रमांक : L24239MH1924PLC001151

३१ मार्च, २०१९ ला संपलेल्या वर्षाकरिता एकल (Standalone) आणि एकत्रित लेखापरिक्षित वित्तीय निष्कर्षांचे विवरण

(₹ लाखांत)

	एकल (Standalone)				एकत्रित	
	संपलेली तिमाही		संपलेले वर्ष		संपलेले वर्ष	
	लेखापरिक्षित	अलेखापरिक्षित	लेखापरिक्षित		लेखापरिक्षित	
	३१.०३.१९ ला संपलेले ३ महिने	३१.०३.१८ ला संपलेले ३ महिने	३१.०३.१९	३१.०३.१८	३१.०३.१९	३१.०३.१८
प्रचलनातून एकूण उत्पन्न	७५१२२	७४८६२	३१२८५३	२८९५८८	३१२८१२	२८९५६५
अपवादात्मक बाबींपूर्वी नफा	२०२३३	१६३६१	६५८८२	५२३७८	६५३९७	५२२१७
करापूर्वी नफा	१९९१६	१६३६१	६६३७१	५४१५८	६८२६६	५३९९७
निव्वळ नफा	१२३०३	१०५५५	४२५३६	३५१९८	४४५३९	३५०७२
कालावधीकरिता एकूण व्यापक उत्पन्न	१२२९६	१०७४८	४१९८७	३५७५७	४३९९०	३५६३१
भरणा केलेले समभाग भांडवल (दर्शनी मुल्य प्रती भाग ₹ १०)	१६९४१	८४७०	१६९४१	८४७०	१६९४१	८४७०
इतर इक्विटी	०.००	०.००	१९७३०१	१९९५२५	१९७०४२	१९७२६३
प्रति भाग मिळकत (ईपीएस) (₹ १० प्रत्येकी)						
बेसिक आणि डायलप्टेड ईपीएस (₹)	७.२६	६.२३	२५.११	२०.७८	२६.२९	२०.७०
वार्षिक नाही						

सूचना :

- ३१ मार्च, २०१९ ला संपलेल्या तिमाही आणि वर्षाकरिता वित्तीय निष्कर्षांच्या तपशिलवार स्वरूपाचे उपरोक्त सार सेबी (लिस्टिंग ऑब्लीगेशन्स अॅण्ड डिस्कलोजर रिक्वायरमेंट्स) रेग्युलेशन्स, २०१५ च्या रेग्युलेशन ३३ अंतर्गत स्टॉक एक्सचेंजेस सोबत फाईल केले. सदर आर्थिक निष्कर्षांचे संपूर्ण स्वरूप कंपनीची वेबसाईट www.gsk-india.com येथे आणि स्टॉक एक्सचेंजेसची वेबसाईट www.nseindia.com आणि www.bseindia.com येथे उपलब्ध आहेत.
- संचालक मंडळ रू. १० प्रत्येकी दर्शनी मुल्याच्या (३१ मार्च, २०१८ ला संपलेले वर्ष, रू. १७.५० प्रती इक्विटी शेअर, सप्टेंबर २०१८ करिता अधिलाभांश भागा पूर्वव्यापी स्वरूपात समायोजित) च्या रू. २०.०० प्रती इक्विटी शेअरच्या लाभांशाची शिफारस करते.
- २० मे, २०१९ रोजी आयोजित मंडळाच्या बैठकीत संचालक मंडळाद्वारे उपरोक्त निष्कर्षांना मान्यता देण्यात आली.



२० मे, २०१९

मंडळाच्या आदेशाद्वारे
अण्णास्वामी वैधीश
व्यवस्थापकीय संचालक
DIN: 1444303